Skip to main content
Publications
Simpson EL, de Bruin-Weller M, Eckert L, Whalley D, Guillemin I, Reaney M, Chen Z, Nelson L, Qin S, Bansal A, Gadkari A. Responder threshold for Patient-Oriented Eczema Measure (POEM) and Children's Dermatology Life Quality Index (CDLQI) in adolescents with atopic dermatitis. Dermatol Ther. 2019 Dec;9(4):799-805. doi: 10.1007/s13555-019-00333-2
Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, Brown M, Reaney M, Mahajan P, Guillemin I, Boguniewicz M, Pariser D. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatology. 2019 Nov 6;19(1):15. doi: 10.1186/s12895-019-0095-3
Augustin M, Feldman S, Poulos C, Gilloteau I, Mange B, Boeri M, Boehm K, Melzer N, Gutknecht M. Patient preferences for treatment of moderate to severe psoriasis: a discrete choice experiment study in Germany. Poster presented at the 28th European Academy of Dermatology and Venereology (EADV) Congress; October 11, 2019. Madrid, Spain.
Carrico J, Jia X, Zhao Y, Zhang J, Brodtkorb T, Mendelsohn A, Wu J, Feldman S, Armstrong A. Cost-effectiveness and budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs. Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a Suppl):S79. doi: 10.18553/jmcp.2019.25.10-a.s1
Gutierrez L, Booth H, Dedman D, Crellin E, Kaye JA, Franzoni C, Arana A, Schmitt-Egenolf M, Sundstrom A, Bystrom C. Case validation of cutaneous lymphoma to minimize protopathic bias. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):645. doi: 10.1002/pds.4864
Carrico J, Jia X, Zhao Y, Zhang J, Brodtkorb TH, Mendelsohn AB, Lowry S, Wu JJ, Feldman SR, Armstrong AW. Budget-impact and cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis from a US health plan perspective. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA.
Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry S, Feldman S, Wu JJ, Armstrong A. Cost-effectiveness of tildrakizumab in U.S. patients with moderate-to-severe plaque psoriasis. Poster presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting; March 1, 2019. Washington, DC. Previously presented at the 2018 Academy of Managed Care Pharmacy (AMCP) Nexus Conference.
Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry S, Feldman S, Armstrong A, Wu JJ. Comparative cost per time in response for tildrakizumab in U.S. patients with moderate-to-severe plaque psoriasis. Poster presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting; March 1, 2019. Washington, DC. Previously presented at the 2018 Academy of Managed Care Pharmacy (AMCP) Nexus Conference.